Press release
Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena International Vaccines Virtual Conference 2021
Keynote Talk: Development of the World's First Triple Antigen Oral SARS Cov-2 Vaccine NEW YORK, Aug. 5, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"Keynote Talk: Development of the World's First Triple Antigen Oral SARS Cov-2 Vaccine\n\n\nNEW YORK, Aug. 5, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its majority-owned company Oravax Medical Inc.'s oral COVID-19 vaccine will be featured in the Keynote Talk at the Arena International Vaccines Virtual Conference 2021 on August 5, 2021, at 9:00 a.m. Eastern. The presentation titled \"Development of the World's First Triple Antigen Oral SARS Cov-2 Vaccine\" will be delivered by Oramed Chief Executive Officer, Nadav Kidron, and Premas Biotech Co-founder & Managing Director, Prabbudha Kundu.\n \n \nOravax's virus-like particle (VLP) vaccine technology targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the COVID-19 virus. \nTo register: https://www.arena-international.com/vaccine-virtual/ \nAbout Oravax Medical Inc.\nOravax was established in 2021 by Oramed Pharmaceuticals Inc., the largest shareholder in Oravax, along with Premas Biotech and certain other shareholders with a mission to bring an oral COVID-19 vaccine to the market. Oravax combines cutting-edge vaccine technology acquired from Premas Biotech and the proprietary POD™ oral delivery technology of Oramed Pharmaceuticals. For more information, please visit www.ora-vax.com \nAbout Oramed Pharmaceuticals\nOramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule. \nFor more information, please visit www.oramed.com.\nForward-looking statements: This press release contains forward-looking st...